A case of severe thrombocytopenia after the first exposure to rifampicin

Severe immune thrombocytopenia is a rare side-effect of rifampicin (RFP) and can be life-threatening. Here, we report the case of a 74-year-old male with tuberculous pleurisy who developed severe thrombocytopenia after first exposure to RFP. Platelet count decreased to 1 × 10(3)/μL after 7 days of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakane, Chinatsu, Nishimoto, Koji, Kishimoto, Ei, Suzuki, Kosuke, Nakagawa, Emiko, Morikawa, Moeko, Murakami, Yurina, Aoshima, Yoichiro, Matsushima, Sayomi, Harada, Masanori, Uto, Tomohiro, Imokawa, Shiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006502/
https://www.ncbi.nlm.nih.gov/pubmed/36915472
http://dx.doi.org/10.1016/j.rmcr.2023.101823
Descripción
Sumario:Severe immune thrombocytopenia is a rare side-effect of rifampicin (RFP) and can be life-threatening. Here, we report the case of a 74-year-old male with tuberculous pleurisy who developed severe thrombocytopenia after first exposure to RFP. Platelet count decreased to 1 × 10(3)/μL after 7 days of treatment with RFP, isoniazid, ethambutol, and pyrazinamide. After all the drugs were discontinued, the platelet count recovered. As thrombocytopenia did not occur after re-administration of drugs other than RFP, the patient was diagnosed with RFP-induced thrombocytopenia. Clinicians should be aware that RFP can induce acute and severe thrombocytopenia even without previous exposure to this drug.

Ejemplares similares